Sobetirome - NeuroVia

Drug Profile

Sobetirome - NeuroVia

Alternative Names: GC-1; NV 1205; QRX-431

Latest Information Update: 30 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Developer NeuroVia; QuatRx Pharmaceuticals; University of California at San Francisco
  • Class Acetic acids; Antihyperlipidaemics; Benzhydryl compounds; Obesity therapies; Phenols; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Adrenoleucodystrophy
  • Discontinued Lipid metabolism disorders; Obesity

Most Recent Events

  • 25 Jul 2018 Phase-I/II clinical trials in Adrenoleucodystrophy (In children, In adolescents) in United Kingdom, Chile (PO) (NCT03196765)
  • 01 Jun 2018 Phase-I/II clinical trials in Adrenoleucodystrophy (In children, In adolescents) in Australia (PO) (NCT03196765)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Adrenoleucodystrophy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top